Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +47.04%
#2 Pons Pons +38.47%
#3 Starpower Starpower +30.38%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +30.10%
#5 TENDIES TENDIES +24.03%
#6 Mubarak Mubarak +23.85%
#7 StonkBroker StonkBroker +21.99%
#8 SkyAI SkyAI +20.90%
#9 Decred Decred +19.75%
#10 PondCoin PondCoin +17.74%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Sofiva Genomics Co.,Ltd. Sofiva Genomics Co.,Ltd.

Sofiva Genomics Co.,Ltd.

6615
Kedudukan dalam Saham #29070
Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan,... Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan, offers a comprehensive range of genetic testing services to both domestic and international clients. The company's diverse diagnostic solutions are designed to support expectant parents, individuals with inherited conditions, and their families. Their extensive prenatal diagnostics include screenings for conditions such as thalassemia carrier status, various microdeletion syndromes, single-gene abnormalities, common chromosomal anomalies, and specific skeletal dysplasia mutations. They also provide multi-gene panel testing for inherited diseases, folate metabolism genetic analysis, carrier screening for spinal muscular atrophy (SMA) and Fragile X syndrome, congenital infection detection, preeclampsia risk assessment, maternal serum screening for Down syndrome, and karyotyping. Within the oncology sector, Sofiva Genomics delivers advanced cancer screenings, dynamic monitoring of tumor activity, and genetic evaluations for hereditary cancer predisposition. This includes specialized panels for women's cancers (breast, colon, ovarian, and endometrial), alongside human papillomavirus (HPV) screening. Furthermore, the company conducts genetic testing for rare diseases and provides specialized reproductive services such as preimplantation genetic diagnosis (PGD) and next-generation sequencing (NGS)-based preimplantation genetic screening (PGS). For newborns, their services encompass comprehensive "baby scans," screenings for hereditary sensorineural hearing loss, congenital central hypoventilation syndrome (CCHS), congenital cytomegalovirus (CMV) infection, and genetic risk assessment for atopic dermatitis. Beyond these specialized offerings, Sofiva Genomics also performs biochemical and chromosomal analyses, complemented by valuable advisory and support services for its clientele.
Harga Saham
$1.07
Modal Pasaran
$23.11M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
4.66%
Negara
TW
Perdagangan Sofiva Genomics Co.,Ltd. (6615)

Kategori

Healthcare
Nisbah P/E bagi Sofiva Genomics Co.,Ltd. (6615)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Sofiva Genomics Co.,Ltd., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Sofiva Genomics Co.,Ltd. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 31.59 -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 35.83 -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 -227.89 -
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 38.69 -
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.